Articles On Telix Pharmaceuticals (ASX:TLX)

At the time of writing, the ASX 200 Health Index (XHJ) is up by over 4%, while the benchmark ASX 200 is rising by 0.5%. Blood products giant CSL (ASX:CSL) delivered a 5% jump in revenue for the first half, but its net profit slid by 5%. Rev...

Telix Pharmaceuticals (ASX:TLX) has announced a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen-und Medizintechnik AG.

The ASX is hosting a goodbye party for Sydney Airport (ASX: SYD) on Wednesday as investors scramble to swap shares in the iconic travel stock one last time. Today, the Supreme Court of New South Wales granted the final approval needed for...

Telix Pharmaceuticals (TLX) is granted an extension for its European regulatory review The notification came from the Danish Medicines Agency, which granted Telix a review period extension of over four months for the company’s application...

Medical imaging software Resonance Health (ASX:RHT) has received the green light in the US for its LiverSmart medical device, making it eligible for recognition by the US government agencies and private insurers. Resonance received confirma...

Today, the S&P/ASX 200 Index (ASX: XJO) has further solidified its position above 7,000 points after going back-to-back with another green day. At the end of the session, the benchmark index finished 1.17% higher at 7,087.7 points. Mo...

Telix Pharmaceuticals (ASX:TLX) has entered an exclusive commercial distribution agreement with Athens-based BIOKOSMOS for its prostate cancer investigational imaging product Illuccix.

Today, the S&P/ASX 200 Index (ASX: XJO) was unable to reclaim lost ground throughout the day. At the end of the session, the benchmark index was 0.24% lower at 6,971.6 points. The overall market ended lower despite the majority of com...

ShareCafeWebinar Recap – LKE, TLX, EMH, ADV Catch up on the full webinar with presentations from Lake Resources (ASX: LKE), Telix Pharmaceuticals (ASX: TLX),  European Metals (ASX: EMH)  & Ardiden Limited (ADV) Webinar Recap...

ShareCafeTelix Pharmaceuticals (ASX: TLX) – Webinar Presentation Dr Christian Behrenbruch – CEO & Managing Director – Telix is a late-stage radiopharmaceutical company developing diagnostic and therapeutic assets using Molecularly Targ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Australian medical device company and global supplier of rapid diagnostic testing devices (RDT), Atomo (ASX: AT1) has scored distribution rights for rapid antigen tests in New Zealand, after being authorised by the New Zealand Ministry of H...

Telix Pharmaceuticals (ASX:TLX) has announced that the first patient has been dosed in its prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program.

Telix Pharmaceuticals (TLX) has first patient dosed in its prostate-specific membrane antigen Telix’s ProstACT study program is evaluating the efficacy of Telix’s lutetium-177 (177Lu)-labelled therapeutic antibodies in all stages of prosta...

Telix Pharmaceuticals (ASX:TLX) has raised $175 million it says will be used to fund the progression of its promising pipeline.

Fears of a market meltdown subsided early today as the ASX 200 fell by just 0.5%, lifted by the bounce back in US stock futures in Asian trading. A rush of US earnings reports in the next few days, along with the two-day Federal Reserve mee...

Key points The Telix Pharmaceuticals share price is down 13% on Monday The company’s December quarterly report revealed a 51% fall in cash reserves It is also conducting a $175 million capital raise The Telix Pharmaceuticals (ASX: TLX...

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.4% to 7,146.3 points. Four ASX shares that are falling more than most t...

Telix Pharmaceuticals (TLX) announces successful $175 million institutional placement which it says will assist with funding of multiple clinical programs and products The company says following completion of the placement it will launch a...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

Melbourne-headquartered nuclear medicine company Telix Pharmaceuticals (ASX: TLX) has completed a $175 million institutional placement to fund final-stage trials of a prostate cancer therapy and the roll-out of its first commercial product...

Healthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The Australian Open has kicked o...

Telix Pharmaceuticals (TLX) enters a trading halt while it plans an upcoming capital raise Currently, there is no information about how much the company is aiming to raise or where the funds will be spent Company shares will be paused unt...

Bearish sentiment is still gripping the local markets, but the ASX managed to pull into itself into positive territory in the last 30 minutes of trading. The benchmark would have slumped more today had it been not for the Mining sector, whi...

ASX-listed oncology company Telix Pharmaceuticals shares have gone into a trading halt as the group prepares to pitch investors for fresh funds. 

Key points ASX-listed Brainchip is flying higher again today after announcing another granted patent The company now holds a significant market capitalisation of over $3.5 billion Based on eligibility criteria, Brainchip could soon be in...

Today, the S&P/ASX 200 Index (ASX: XJO) took a ride to the downside with a powerful blow to tech shares. At the end of the session, the benchmark index finished 1.08% lower at 7,393.9 points. Concerns of interest rate hikes caused by...

Today, the S&P/ASX 200 Index (ASX: XJO) disappointed investors with another red showing. At the end of the session, the benchmark index was down 0.71% to 7,710.7 points. Unfortunately, it was another somewhat sombre showing across the...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

ASX biotech shares were a mixed bag in 2021. Several of the majors came in behind their benchmarks whilst many smaller players outshone the pack. The sector has been the benefactor of long-term tailwinds in diagnostics and demand for nove...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

21 Dec 2021 - Telix Pharmaceuticals' (ASX:TLX) first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer at an institute in …

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is continuing its good run this week amid a company announcement on its study to treat bladder cancer. The biopharmaceutical company has informed investors it has delivered its first dos...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.75% to 7,346.6 points. Four ASX shares that are climbing more than most today are listed bel...

Telix Pharmaceuticals’ (TLX) first patient has been dosed with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC) TLX250-CDx is being developed by Telix for the purpose of determining whether “indeterminate renal masses” are either...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is all over the place in early trade this morning after the company announced a significant update. The biotechnology company’s shares opened higher today, peaking at $8.15, before plung...

The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of writing, compared to the broader index which is down by 0.22%. Cannabis-based medtech company, Emyria Limited (ASX:EMD), has signed an agreement with Seattle-based Cyd...

The US Food and Drug Administration approves Telix Pharmaceuticals (TLX) prostate cancer imaging product, Illuccix The approval of the product offers improved imaging to detect metastatic prostate cancer and determine the most appropriate...

ASX biotech shares provided a mixed bag of results in 2021 with many names underperforming their benchmarks while others flourished amid COVID-19 related tailwinds. Whilst many Aussie biotechs came in behind the pack this year, the S&...

The ASX 200 closed Friday’s trading lower by 0.38%, but was still up 1.6% for the week. The local market was relatively quiet today as nervous investors awaited the key US CPI data to be released tonight (US time). Investors could be bracin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a disappointing note. At the time of writing, the benchmark index is down 0.5% to 7,349.8 points. Four ASX shares that are not letting that stop them...

Shares in Melbourne-based oncology company Telix Pharmaceuticals Ltd (ASX: TLX) are currently down 2% in the red today, trading at $7.35 apiece. Investors aren’t responding enthusiastically to a company announcement early on during Friday’...

Telix Pharmaceuticals’ (TLX) marketing authorisation application (MAA) submission in Europe for the registration of Illuccix has advanced to the final stage of regulatory review Illuccix is a positron emission tomography (PET) agent for th...

Investing in ASX biotech shares was an underwhelming affair in November. As a basket, the sector lagged key benchmarks, and many names saw substantial declines in value over the month. Renewed fears from the Omicron COVID-19 variant saw in...

08 Dec 2021 - Telix Pharmaceuticals (ASX:TLX) has entered into an exclusive commercial distribution agreement with NUCLIBER for its prostate cancer investigational imaging product …

Telix Pharmaceuticals (TLX) enters an exclusive commercial distribution agreement with NUCLIBER S.A Spain for its prostate cancer investigational imaging product, Illuccix Under the agreement, NUCLIBER will be the distributor and local rep...

Telix Pharmaceuticals (ASX:TLX) has announced an exclusive licence agreement for a novel positron emission tomography radiotracer originating from the Université catholique de Louvain in Belgium.

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product Illuccix, a PET imaging agent, targets a prostate specific membrane antigen which appears on more than 90 per cent...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...